Significant dose escalation of Idarubicin in the treatment of low risk aggressive non-Hodgkin's lymphoma leads to increased hematotoxicity and decreased efficacy: Nine year follow up of a phase-I/II trial of the DSHNHL

2008 | conference abstract. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Significant dose escalation of Idarubicin in the treatment of low risk aggressive non-Hodgkin's lymphoma leads to increased hematotoxicity and decreased efficacy: Nine year follow up of a phase-I/II trial of the DSHNHL​
Hohloch, K.; Zwick, C.; Zeipert, M.; Kaiser, U.; Engert, A.; Reiser, M. & Hoeffkes, H.-G. et al.​ (2008)
Annals of Oncology, 19 ​10th International Conference on Malignant Lymphoma​, Lugano, SWITZERLAND.
Oxford​: Oxford Univ Press.

Copy

Further links

Documents & Media

License

GRO License GRO License

Details

Authors
Hohloch, Karin; Zwick, Carsten; Zeipert, M.; Kaiser, U.; Engert, Andreas; Reiser, M.; Hoeffkes, Heinz-Gert; Kroschinsky, Frank; Meesters, R.; Feller, A.; Leoffler, M.; Truemper, Lorenz H.; Pfreundschuh, Michael
Issue Date
2008
Status
published
Publisher
Oxford Univ Press
Journal
Annals of Oncology 
Conference
10th International Conference on Malignant Lymphoma
Conference Place
Lugano, SWITZERLAND
ISSN
0923-7534
Extent
218

Export Metadata

Refman EndNote BibTeX RefWorks Excel CSV

Reference

Citations